Alerts will be sent to your verified email
Verify Email
CONCORD
|
Concord Drugs
|
Curis Lifesciences
|
Pharmaids Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
2.78 % | 76.73 % | 0.42 % |
|
5yr average Equity Multiplier
|
1.87 | 1.91 | 1.31 |
|
5yr Average Asset Turnover Ratio
|
0.84 | 1.07 | 0.18 |
|
5yr Avg Net Profit Margin
|
1.59 % | 8.37 % | -26.11 % |
|
Price to Book
|
3.11 | 0.0 | 2.04 |
|
P/E
|
189.8 | 17.48 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
233.27 Days | 45.79 Days | -124.59 Days |
|
Inventory Days
|
152.22 Days | 77.61 Days | 79.26 Days |
|
Days Receivable
|
106.22 Days | 65.45 Days | 54.5 Days |
|
Days Payable
|
74.71 Days | 245.93 Days | 383.86 Days |
|
5yr Average Interest Coverage Ratio
|
1.69 | 5.43 | -741.3 |
|
5yr Avg ROCE
|
8.41 % | 36.41 % | -21.3 % |
|
5yr Avg Operating Profit Margin
|
9.1 % | 16.92 % | -35.99 % |
|
5 yr average Debt to Equity
|
0.55 | 0.12 | 0.16 |
|
5yr CAGR Net Profit
|
-26.55 % | 65.64 % | n/a |
|
5yr Average Return on Assets
|
1.46 % | 9.21 % | -13.12 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.39 % | 68.03 % | 32.99 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
2.26 % | 0.0 | 23.04 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Concord Drugs
|
Curis Lifesciences
|
Pharmaids Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|